Company

BianoScience was founded as a Spin-off from the Friedrich-Schiller-University of Jena, Germany, in 2011 as a privately owned biotech company. Our focus has been on oligonucleotides ever since. We developed chiRNA, a therapeutic RNAi prodrug platform. chiRNA consists of a chimeric siRNA deactivated by a peptide cap. Disease-specific proteases cleaving off the peptide activate the siRNA selectively in diseased tissue or cells. Applications of the chiRNA platform include anticancer and antiviral therapies.
As stepping into late-preclinical phase we required gramm-scale amounts of GMP material, which was hard to get on the market.

For this reason, in 2017 we founded BianoGMP focused on small scale GMP-oligonucleotide services, moved to Gera, installed clean rooms, synthesizer and downstream processes. During this time BianoGMP greatly appreciated funding obtained from the European Regional Development Fund and the state of Thuringia enabling us to increase our quality, receive a GMP certificate and access the market. Since 2020 we are serving customers all over the world with GMP oligonucleotides for initial clinical trials.

In 2023 we partnered with EUROAPI – a specialist in large scale oligonucleotide and other API-production. In this partnership, BianoGMP will gain its production capabilities, install new clean rooms, large-scale synthesizers and downstream process in order to provide larger batch sizes and support customers stepping into later clinical development.